Khurram Jamil, Md Email & Phone Number

Manage NAVIGATE, a seamless, adaptive Phase 2b/3 Trial in NASH cirrhosis patients assessing safety and efficacy of Belapectin (antifibrotic, Galectin-3 receptor inhibitor) for prevention of esophageal varices in pts with NASH cirrhosis. Assessing liver related clinical outcomes and NITs as other end points. Global trial in US, LATAM, EU and Asia. Manage regulatory interactions with FDA as well as communication/publication strategy related to Belapectin development program. Collaborate on… Show more Manage NAVIGATE, a seamless, adaptive Phase 2b/3 Trial in NASH cirrhosis patients assessing safety and efficacy of Belapectin (antifibrotic, Galectin-3 receptor inhibitor) for prevention of esophageal varices in pts with NASH cirrhosis. Assessing liver related clinical outcomes and NITs as other end points. Global trial in US, LATAM, EU and Asia. Manage regulatory interactions with FDA as well as communication/publication strategy related to Belapectin development program. Collaborate on formulation development and partnership opportunities to expand the pipeline. Show less

New Jersey

Clinical Development lead for Terlipressin program, designed phase 3 CONFIRM trial under SPA, successful execution of largest ever trial in HRS pts. in 2020, moderated CRDAC advisory committee meeting with positive vote. Approval of Terlivaz in September of 2022. In 2023, took over the role of Global Program Head role, responsible for leading and managing teams for launch as well as global extension programs for the brand.

New Jersey

Managing PoC, late phase clinical development across number of therapeutic areas including Cardiovascular, Transplant, Respiratory, Hepatology in critical care in-hospital setting. Leading teams for regulatory filings with FDA, TGA, PMDA. Proven track record of publications, patent filings and presentations at clinical symposia.

Hampton, Nj

Leading the Terlipressin Development for Hepatorenal Syndrome in North America. Successfully led approval of Terlipresin in Australia in 2012. Medical Lead for the REVERSE trial. Led Clinical Program for approval of INOmax for CV Surgery in Japan.

New Jersey

Managing clinical trials for phase III in CNS, Anesthesia. Regulatory filings with FDA and EMA for novel, first in class molecule of Sugammadex.

Md, General Surgery Residency Program

Post Graduate Medical Education

Orthopedics

Research Fellow- Rheumatology

Bachelor Of Medicine, Bachelor Of Surgery (Mbbs), Medicine

M.B; B.S

Leadership Training